MWA
CHRS icon

Medallion Wealth Advisors’s Coherus Oncology CHRS Stock Holding History

Medallion Wealth Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.4K Hold
15,000
– – 0.01% 605
2025
Q4 		$21.3K Hold
15,000
– – 0.01% 629
2025
Q3 		$24.6K Buy
15,000
+9,000
+150% +$10K 0.01% 597
2025
Q2 		$4.56K Hold
6,000
– – ﹤0.01% 850
2025
Q1 		$4.84K Buy
6,000
+3,930
+190% +$4.52K ﹤0.01% 792
2024
Q4 		$2.86K Buy
+2,070
New +$2.32K ﹤0.01% 814

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Medallion Wealth Advisors's CHRS Position: Q1 2026 in Review

Medallion Wealth Advisors held its Coherus Oncology (CHRS) position steady in Q1 2026 at 15,000 shares worth $25.4K. The position accounts for 0.01% of the portfolio, ranked #605.

Medallion Wealth Advisors first reported a position in CHRS in Q4 2024 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Medallion Wealth Advisors held 15,000 shares of Coherus Oncology worth $25.4K as of Q1 2026.
  • Medallion Wealth Advisors left its Coherus Oncology share count unchanged in Q1 2026.
  • Coherus Oncology made up 0.01% of Medallion Wealth Advisors's portfolio in Q1 2026, its #605 holding.
  • Medallion Wealth Advisors first reported a position in Coherus Oncology in Q4 2024 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.